MétaCan
Menu
Retour à la cohorte
Enregistrement W4280573135 · doi:10.1016/s2215-0366(22)00103-1

The EMPOWER blended digital intervention for relapse prevention in schizophrenia: a feasibility cluster randomised controlled trial in Scotland and Australia

2022· article· en· W4280573135 sur OpenAlexaff
Andrew Gumley, Simon Bradstreet, John Ainsworth, Stephanie Allan, Mario Álvarez‐Jiménez, Lorna Aucott, Max Birchwood, Andrew Briggs, Sandra Bucci, Sue Cotton, Lidia Engel, Paul French, Reeva Lederman, Shôn Lewis, Matthew Machin, Graeme MacLennan, Hamish J. McLeod, Nicola McMeekin, Emma Morton, John Norrie, Matthias Schwannauer, Swaran P. Singh, Suresh Sundram, Andrew Thompson, Chris Williams, Alison R. Yung, John Farhall, John Gleeson

Notice bibliographique

RevueThe Lancet Psychiatry · 2022
Typearticle
Langueen
DomainePsychology
ThématiqueDigital Mental Health Interventions
Établissements canadiensUniversity of British Columbia
Organismes subventionnairesNational Health and Medical Research CouncilAustralian Research CouncilMedical Research CouncilHealth Technology Assessment ProgrammeEconomic and Social Research CouncilUniversity of MelbourneChief Scientist OfficeUniversity of GlasgowDepartment of Health and Social CareAlan Turing InstituteScottish GovernmentEngineering and Physical Sciences Research CouncilNational Institute for Health and Care ResearchNHS Health Scotland
Mots-clésMedicineRandomized controlled trialCluster randomised controlled trialIntervention (counseling)TriageRelapse preventionMental healthPsychiatryFamily medicinePsychology

Résumé

récupéré en direct d'OpenAlex

BACKGROUND: Early warning signs monitoring by service users with schizophrenia has shown promise in preventing relapse but the quality of evidence is low. We aimed to establish the feasibility of undertaking a definitive randomised controlled trial to determine the effectiveness of a blended digital intervention for relapse prevention in schizophrenia. METHODS: This multicentre, feasibility, cluster randomised controlled trial aimed to compare Early signs Monitoring to Prevent relapse in psychosis and prOmote Well-being, Engagement, and Recovery (EMPOWER) with treatment as usual in community mental health services (CMHS) in Glasgow and Melbourne. CMHS were the unit of randomisation, selected on the basis of those that probably had five or more care coordinators willing to participate. Participants were eligible if they were older than 16 years, had a schizophrenia or related diagnosis confirmed via case records, were able to provide informed consent, had contact with CMHS, and had had a relapse within the previous 2 years. Participants were randomised within stratified clusters to EMPOWER or to continue their usual approach to care. EMPOWER blended a smartphone for active monitoring of early warning signs with peer support to promote self-management and clinical triage to promote access to relapse prevention. Main outcomes were feasibility, acceptability, usability, and safety, which was assessed through face-to-face interviews. App usage was assessed via the smartphone and self-report. Primary end point was 12 months. Participants, research assistants and other team members involved in delivering the intervention were not masked to treatment conditions. Assessment of relapse was done by an independent adjudication panel masked to randomisation group. The study is registered at ISRCTN (99559262). FINDINGS: We identified and randomised eight CMHS (six in Glasgow and two in Melbourne) comprising 47 care coordinators. We recruited 86 service users between Jan 19 and Aug 8, 2018; 73 were randomised (42 [58%] to EMPOWER and 31 [42%] to treatment as usual). There were 37 (51%) men and 36 (49%) women. At 12 months, main outcomes were collected for 32 (76%) of service users in the EMPOWER group and 30 (97%) of service users in the treatment as usual group. Of those randomised to EMPOWER, 30 (71%) met our a priori criterion of more than 33% adherence to daily monitoring that assumed feasibility. Median time to discontinuation of these participants was 31·5 weeks (SD 14·5). There were 29 adverse events in the EMPOWER group and 25 adverse events in the treatment as usual group. There were 13 app-related adverse events, affecting 11 people, one of which was serious. Fear of relapse was lower in the EMPOWER group than in the treatment as usual group at 12 months (mean difference -7·53 (95% CI -14·45 to 0·60; Cohen's d -0·53). INTERPRETATION: A trial of digital technology to monitor early warning signs blended with peer support and clinical triage to detect and prevent relapse appears to be feasible, safe, and acceptable. A further main trial is merited. FUNDING: UK National Institute for Health Research Health Technology Assessment programme and the Australian National Health and Medical Research Council.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction machine sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.

score de la tête « metaresearch » (Codex)0,005
score de la tête « metaresearch » (Gemma)0,007
Version: metacan-v3-hybrid-931329e0061cStatut de validation: machine_predicted_unvalidated
Catégories candidatesaucune
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Essai randomisé · Signal consensuel: Essai randomisé
GenreSignal candidat: Empirique · Signal consensuel: Empirique
Score de désaccord entre enseignants0,025
Score d'incertitude au seuil0,050

Scores du classifieur distillé par catégorie (deux têtes)

CatégorieCodexGemma
Métarecherche0,0050,007
Méta-épidémiologie (sens strict)0,0010,001
Méta-épidémiologie (sens large)0,0030,003
Bibliométrie0,0010,001
Études des sciences et des technologies0,0010,002
Communication savante0,0010,002
Science ouverte0,0010,002
Intégrité de la recherche0,0020,003
Charge utile insuffisante (le modèle a refusé de juger)0,0080,000

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,047
Tête enseignante GPT0,390
Écart entre enseignants0,343 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.

Les modèles n’ont appliqué aucune catégorie : rien dans la taxonomie ne correspondait à ce travail.
Devis d'étudeEssai randomisé
Domainenon disponible
GenreEmpirique

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations72
Publié2022
Routes d'admission1
Résumé présentnon

Explorer davantage

Même revueThe Lancet PsychiatryMême sujetDigital Mental Health InterventionsTravaux en français237 207